Literature DB >> 36003352

Ralstonia mannitolilytica: an emerging multidrug-resistant opportunistic pathogen in a tertiary care hospital setting.

Tasneem Siddiqui1, Sangram Singh Patel1, Richa Sinha1, Ujjala Ghoshal1, Chinmoy Sahu1.   

Abstract

Introduction: Ralstonia mannitolilytica is a rare opportunistic pathogen capable of causing a serious infection in immunocompromised patients. Our objective was to describe all cases of R. mannitolilytica bloodstream infection identified within 2 years at our tertiary care centre, focusing on clinical characteristics, risk factors, antibiotic sensitivity patterns, management and outcomes. Case Series: We compiled a descriptive case series including 14 non-duplicate R. mannitolilytica isolates obtained from bloodstream infection samples from the microbiology laboratory of a tertiary care centre from June 2019 to June 2021. All isolates were initially identified based on their morphological properties and biochemical reactions, and then underwent matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) examination for confirmation of identity. Antibiotic susceptibility testing was performed using the Kirby-Bauer disc diffusion method and Vitek 2. All 14 patients presented with symptoms of fever and/or chills, and a positive blood culture for R. mannitolilytica . After 48 h of incubation, no Ralstonia growth was reported from any of the current environmental or pharmaceutical water samples. Chemotherapy (9/14), mechanical ventilation (4/14), steroid use (2/14) and diabetes mellitus (1/14) were associated risk factors in our patients. The antibiotic sensitivity panel showed maximum resistance to aminoglycosides (64.3%) and no resistance to cefoperazone/sulbactum. Patients received treatment with cefoperazone/sulbactum and meropenem or ceftazidime. Thirteen patients recovered with antibiotic therapy and one patient succumbed to his illness.
Conclusion: R. mannitolilytica can cause bloodstream infections in immunocompromised patients. It is likely to be missed or underreported due to lack of clinical awareness. MALDI-TOF MS is helpful in rapid identification. R. mannitolilytica is resistant to many routinely used antibiotics, including carbapenems.
© 2022 The Authors.

Entities:  

Keywords:  Gram-negative; MALDI-TOF-MS; Ralstonia mannitolilytica; nosocomial pathogen

Year:  2022        PMID: 36003352      PMCID: PMC9394538          DOI: 10.1099/acmi.0.000367

Source DB:  PubMed          Journal:  Access Microbiol        ISSN: 2516-8290


Introduction

– aerobic Gram-negative non-fermentative rods – are environmental organisms commonly found in water and soil, but are now emerging as opportunistic pathogens causing infections in immunocompromised patients [1]. They could be an aetiological agent in common source nosocomial outbreaks due to contamination of parenteral fluid and medical equipment that is considered to be sterile [2]. are known to cause sepsis, meningitis and central venous catheter-associated bacteraemia [3]. Of late several case reports of infections by have been seen from India and worldwide [4-12]. Many case reports have highlighted as causing bacteraemia and sepsis [4-11]. Lampropoulos et al. (2021) and Rajendran et al. (2022) highlighted the organism as an emerging opportunistic pathogen causing sepsis in neonatal intensive care units [9, 10] . Carreira et al. (2020) emphasized the role of in endocarditis [12]. The tendency of R.mannitolilytica to form biofilm enhances the organism’s survival in the environment (including the hospital environment), and plays a role in frequent antibiotic resistance [13]. There are currently no clear treatment guidelines or Clinical and Laboratory Standards Institute (CLSI) breakpoints for . Treatment is challenging, as this species is frequently resistant to many antibiotics [1]. Resistance to many of the β-lactam class of antibiotics, including the carbapenems, is generally observed in . blaOXA-22 and blaOXA-60 are class D carabapenmase genes that are commonly associated with species [14]. Treatment is based on the antibiotic susceptibility profile of the isolate [1]. There are very few case reports on this rare opportunistic pathogen in bloodstream infections from India. In this case series, we summarize the clinical characteristics of 14 patients with nosocomial bloodstream infections caused by R.mannitolilytica in the last 2 years, and analyse their risk factors, management and outcomes. We have also reported drug susceptibility patterns, which may help in the management of patients infected with this bacterium.

Case series

This case series includes clinically significant non-duplicate culture isolates of species obtained from suspected bloodstream infections in microbiology laboratory of a tertiary care centre of northern India. These cases occurred between June 2019 and June 2021 in the Departments of Haematology, Critical Care medicine, Gastro-medicine, Pulmonary Medicine and Endocrine Surgery. Written informed consent for publication of clinical details was obtained from the patients before the study. A study proforma was designed, which included patient demographic data, clinical details, underlying risk factors during the episode of infection, duration of hospital stay, treatment received and outcomes.

Sample processing and identification of isolates

Blood samples were inoculated into aerobic and anaerobic blood culture bottles (Becton Dickinson Diagnostics, USA) and incubated in the in BACTEC blood culture system (BD Diagnostics, USA). Once flagged positive, a Gram stain was performed from the bottle and the broth was plated onto 5 % sheep blood agar and MacConkey agar. The plates were incubated at 37 °C in ambient air and then inspected for growth at 24 h and again at 48 h. All of the culture media used were obtained from HiMedia Laboratories (Mumbai, India). The bacterial isolates were first identified using the routine staining and biochemical tests used in our laboratory [15]. The biochemical reactions for this Gram-negative bacillus revealed the results as follows: catalase-positive, oxidase-positive, motile, non-fermenting, methyl red-negative, Voges–Proskauer-negative, indole-negative, triple sugar iron agar – K/K (alkaline/alkaline), and urease-negative. Citrate was utilized but aesculin and gelatin were not hydrolyzed. and were differentiated on the basis of nitrate reduction (negative in ) and acidification of d-arabitol and mannitol (both negative in ) [16]. The identity of all the isolates was confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using the VITEK MS system (bioMérieux, Marcy-l’Etoile, France). Briefly, one bacterial colony of each isolate was spotted directly onto a single well of a disposable, barcode-labelled Vitek MS-DS target slide (bioMérieux, Marcy l’Etoile, France) and overlaid with 1 µl of saturated α-cyano-4-hydroxycinnamic acid (CHCA) (Vitek MS-CHCA, bioMérieux, Marcy l’Etoile, France) matrix and then air-dried. ATCC 8739 was used as the quality control strain and was transferred directly to designated spots on the target slide as per the recommendation of the manufacturer. The target slide with all prepared isolates was then loaded into the VITEK MS system to acquire the mass spectra of bacterial proteins [17]. Finally, the mass spectra acquired for each isolate were compared to the known mass spectra contained in the SARAMIS database. The software compares the spectra and generates a numerical value (score value) based on the similarities between the observed and stored data sets. A score value above 2.0 is generally considered to be a valid species level identification and values between 2.0 and 1.7 represent reliable genus-level identification.

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method on Müller–Hinton agar and with an automated method (Vitek 2, bioMérieux) [18]. Antibiotic sensitivity was tested as per the Clinical and Laboratory Standards Institute (CLSI) guidelines [19]. As there were no CLSI breakpoints or zone diameters available for , the results were interpreted using the CLSI breakpoints for spp. [19]. ATCC 27853 and ATCC 25922 were put up as controls.

Environmental surveillance sampling

Environmental samples were collected from different wards from which isolates had been obtained by an infection control nurse. Commercially available sterile swabs (HiMedia Laboratories, Mumbai, India) were used to collect samples from the patients’ immediate surroundings, bed rails, tubing and medical devices. Samples from unused sterile intravenous fluids, liquid soaps and disinfectants and water (drinking water and tap water) were obtained in a sterile universal container. Air sampling was performed using a sieve impactor.

Processing of environmental samples

Swabs were incubated in brain heart infusion (BHI) media at 37 °C for 18–24 h. After 24 h, BHI media was inspected visually for any turbidity or growth. A small volume of sample was then taken with the help of an inoculating loop and sub-cultured on blood and MacConkey agar. The culture plates were further incubated for 24 h at 37 °C. Any positive growth was further identified using Gram staining and appropriate biochemical tests.

Statistical analysis

Statistical tests were performed using SPSS for Windows version 14 (SPSS, Inc., Chicago, IL, USA) for descriptive statistics. Categorical data were described using numbers and percentages.

Results

A total of 14 cases of were reported from our hospital over a period of 2 years. All of the patients presented with symptoms of fever and/or chills, and a positive blood culture for . We carried out comprehensive environmental sampling from various sites in our hospital. However, after 48 h of incubation all of the cultures were found to be sterile. The age of the patient population ranged from 8 to 58 years with a median age of 15.5 years. The number of males and females enrolled in the study were 10 and 4, respectively, with a M : F ratio of 2.5 :  1. Detailed demographic and clinical characteristics of the patients are illustrated in Table 1. The majority of the patients with infection had haematological malignancy (8/14) and there was one patient each with breast carcinoma, dengue haemorrhagic shock syndrome, decompensated chronic liver disease, acute respiratory distress syndrome, acute necrotizing pancreatitis and severe coronavirus disease 2019 (COVID-19) pneumonia. The average duration of hospital stay was 29 days (range 10–58 days) and the mean time of development of infection after hospitalization was 15.1 days. Chemotherapy (9/14), mechanical ventilation (4/14) and steroid (2/14) use were the most common risk factors in these patients.
Table 1.

Demographic and clinical characteristics of patients

Patient no.

Age range

Clinical diagnosis

Risk factors

1

21–30

Dengue haemorrhagic shock syndrome

Gastrointestinal surgery within 30 days, mechanical ventilation, steroid use

2

51–60

Decompensated chronic liver disease

Diabetes mellitus

3

51–60

Acute respiratory distress syndrome

Mechanical ventilation, anti-tubercular treatment

4

31–40

Acute necrotizing pancreatitis

Mechanical ventilation

5

11–20

Acute lymphoblastic leukaemia

Chemotherapy

6

51–60

Severe COVID-19 pneumonia

Mechanical ventilation, steroids

7

11–20

Acute myeloid leukaemia

Chemotherapy

8

51–60

Breast carcinoma

Chemotherapy

9

11–20

Acute myeloid leukaemia

Chemotherapy

10

1–10

Hodgkin’s lymphoma

Chemotherapy

11

11–20

Hodgkin’s lymphoma

Chemotherapy

12

11–20

Acute myeloid leukaemia

Chemotherapy

13

11–20

Acute lymphoblastic leukaemia

Chemotherapy

14

11–20

Acute myeloid leukaemia

Chemotherapy

Demographic and clinical characteristics of patients Patient no. Age range Clinical diagnosis Risk factors 1 21–30 Dengue haemorrhagic shock syndrome Gastrointestinal surgery within 30 days, mechanical ventilation, steroid use 2 51–60 Decompensated chronic liver disease Diabetes mellitus 3 51–60 Acute respiratory distress syndrome Mechanical ventilation, anti-tubercular treatment 4 31–40 Acute necrotizing pancreatitis Mechanical ventilation 5 11–20 Acute lymphoblastic leukaemia Chemotherapy 6 51–60 Severe COVID-19 pneumonia Mechanical ventilation, steroids 7 11–20 Acute myeloid leukaemia Chemotherapy 8 51–60 Breast carcinoma Chemotherapy 9 11–20 Acute myeloid leukaemia Chemotherapy 10 1–10 Hodgkin’s lymphoma Chemotherapy 11 11–20 Hodgkin’s lymphoma Chemotherapy 12 11–20 Acute myeloid leukaemia Chemotherapy 13 11–20 Acute lymphoblastic leukaemia Chemotherapy 14 11–20 Acute myeloid leukaemia Chemotherapy MALDI-TOF-MS identified all 14 isolates as with confidence values of 99.9 %. All of the isolates (100 %) were sensitive to cefoperazone/sulbactum (Fig. 1). It was determined that 64.3 % (9/14) and 50 % (7/14) of isolates were resistant to aminoglycosides (amikacin and gentamicin) and ceftazidime, respectively; 42.8 % (6/14) of isolates were resistant to each of piperacillin/tazobactam, cotrimoxazole and carbapenems (imipenem and meropenem); and 21.4 % (3/14) and 14.3 % (2/14) of isolates were resistant to fluoroquinolones (ciprofloxacin and levofloxacin) and cefepime, respectively.
Fig. 1.

Antimicrobial susceptibility of 14 clinical isolates of determined using the CLSI standards and interpreted as per the CLSI breakpoints for spp.

Antimicrobial susceptibility of 14 clinical isolates of determined using the CLSI standards and interpreted as per the CLSI breakpoints for spp. The following antibiotics were administered to patients after antibiotic susceptibility testing and according to the clinicians’ decisions: cefoperazone/sulbactam was given to 10 (71.4 %) patients, meropenem to 3 (21.4 %) patients and ceftazidime to 1 (7.2 %) patient. Thirteen patients recovered with antibiotic therapy and one patient succumbed to his illness, but the cause of death for this patient was complications of COVID-19 (Table 2).
Table 2.

Timeline of infection, identification, management and outcome for the patients

Patient no.

Duration of hospital stay (days)

Time from admission to development of infection (days)

Identity of isolates

(MALDI-TOF)

Treatment received

Outcome/follow-up

1

11

5

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

2

15

11

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

3

58

27

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

4

35

5

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

5

10

8

R. mannitolilytica

Meropenem+colistin

Recovered

6

49

26

R. mannitolilytica

Meropenem+colistin

Dead

7

20

8

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

8

10

6

R. mannitolilytica

Meropenem+colistin

Recovered

9

21

6

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

10

40

30

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

11

29

25

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

12

52

32

R. mannitolilytica

Ceftazidime+amikacin

Recovered

13

31

12

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

14

28

10

R. mannitolilytica

Cefoperazone/sulbactum

Recovered

Timeline of infection, identification, management and outcome for the patients Patient no. Duration of hospital stay (days) Time from admission to development of infection (days) Identity of isolates (MALDI-TOF) Treatment received Outcome/follow-up 1 11 5 Cefoperazone/sulbactum Recovered 2 15 11 Cefoperazone/sulbactum Recovered 3 58 27 Cefoperazone/sulbactum Recovered 4 35 5 Cefoperazone/sulbactum Recovered 5 10 8 Meropenem+colistin Recovered 6 49 26 Meropenem+colistin Dead 7 20 8 Cefoperazone/sulbactum Recovered 8 10 6 Meropenem+colistin Recovered 9 21 6 Cefoperazone/sulbactum Recovered 10 40 30 Cefoperazone/sulbactum Recovered 11 29 25 Cefoperazone/sulbactum Recovered 12 52 32 Ceftazidime+amikacin Recovered 13 31 12 Cefoperazone/sulbactum Recovered 14 28 10 Cefoperazone/sulbactum Recovered

Discussion and conclusion

Few cases of infections caused by R.mannitolilytica have been reported due to limited awareness of the pathogen. The development of modern medical care, inappropriate and unnecessary use of broad-spectrum antibiotics, and the extensive use of various immunosuppressants have caused increased rates of opportunistic infections from organisms such as R.mannitolilytica. The prevalence of infection is increasing notably, even without person-to-person transmission [1]. exist widely in external aqueous environments, including municipal water and medical water purification systems [20, 21]. As the bacteria can pass through 0.2 µm filters during the sterilization process, medical products may be contaminated during the manufacturing phase [22]. can create biofilms on the surfaces of medical supplies and produce toxins [13]. Most infectious cases caused by species are due to the use of contaminated solutions, chlorhexidine, saline solution, blood products and sterile water as well as the colonization of medical devices (tap water and water used for haemodialysis, bronchoscope flushing and heparin for flushing) [3, 23, 24]. In this case series we have described 14 nosocomial cases of bloodstream infections caused by , although we could not track their source. All of our patients were at high risk of infection. The high-risk factors listed in the literature are cancer, blood vessel catheters, mechanical ventilation and other immunocompromised conditions [1, 25] that were also found in our study. The most frequent risk factor in the study population was the use of chemotherapy and steroids, which could be why most of the patients in the study had malignancy, which itself is an immunocompromised state [3]. Further, these patients received chemotherapy as well as immunosuppressant drugs [3]. Hence, such patients are vulnerable to opportunistic infections such as , which is non-harmful to healthy persons [1]. Long-term use of steroids also causes an increase in the rate of infections due to deranged cellular immunity. Central lines are essential in malignancy patients for long-term chemotherapy infusions, and infection of central lines might happen during the insertion procedure as well as during the maintenance period. Biofilm formation in the central lines might cause bacteria to harbour and cause central line-associated bloodstream infections [4]. Blood products through central lines might help in the formation of biofilms that might cause central line infections in these cases. It is well accepted that, over time, the presence of endotracheal tubes for mechanical ventilation increases the risk of bacterial colonization and the development of infection. Similarly, it is conceivable that , a water-borne bacterium cultured from respiratory devices, may have the capacity to colonize the airways; its capacity to generate biofilms, like species, enables it to cause infection in patients who are mechanically ventilated for longer periods [21]. Diabetes itself causes increased infections due to unbalanced blood sugar levels in patients. All of these patients had prolonged hospital stays, which might have led to acquisition of this bacterium. Boattini et al. (2018) reported that this pathogen is an important cause of nosocomial bacteraemia in diabetics, preterm infants, solid organ and haematological malignancy patients, and patients with end-stage renal disease [4]. Thomas et al. (2021) reported it to cause bacteraemia and gastroenteritis in a patient with rheumatoid arthritis. Diagnosis and management of spp. infections is challenging. First, there is the difficulty of correctly identifying and differentiating between spp. members using routine laboratory analyses, because they have very similar biochemical patterns to each other and to other bacterial genera, such as the complex [1]. MALDI-TOF showed good performance regarding the identification of in a previous study using isolates from patients with cystic fibrosis [26]. Although 16S rDNA is the reference method for identifying micro-organisms, it is costly and cumbersome. In the present study, MALDI-TOF correctly identified all of the isolates rapidly. Therefore, in comparison to the turnaround time and PCR identification cost of the 16S sequencing method, MALDI-TOF MS would be a better choice for identification of . Our results support the general consensus that MALDI-TOF MS can provide rapid and accurate results [27]. Second, are frequently resistant to numerous different types of antibiotics, including several beta-lactams and most of the aminoglycosides [1]. The organism may produce various enzymes that can hydrolyze antibiotics. These can confer resistance to a broad range of antibiotics, including benzylpenicillin, narrow-spectrum cephalosporins, ceftazidime, aztreonam and the carbapenems [26]. As currently there are no clear treatment guidelines for and the data from various case reports reveal a notable heterogeneity in the percentage of antibiotic resistance amongst isolates, in the course of treatment we advocate using antibiotic susceptibility testing to adjust the use of antimicrobial agents. Our antibiotic susceptibility pattern showed maximum resistance to aminoglycosides and no resistance to cefoperazone/sulbactum. Hence most of our patients were treated with cefoperazone/sulbactum or a with some other third-generation cephalosporins. Daxboeck et al. reported carbapenem resistance in 12 out of their 30 strains [28], which is consistent with our study, where we found carbapenem resistance in 6 out of 14 isolates. Thus meropenem was only used for seriously ill patients whose antibiograms showed sensitivity to meropenem. A 93 % (13/14) recovery rate in the study patients supports the view that early diagnosis and early initiation of appropriate antibiotics are required for good outcomes in these patients. Even though is not recognized as a major pathogen, clinicians and microbiologists should pay attention to the potential of this opportunistic bacterium, which is able to cause bloodstream infections, as it has certain notable characteristics, such as multidrug resistance, the ability to survive in water supplies and resistance to disinfection practices. Prompt diagnosis and subsequent administration of antibiotics in line with antimicrobial susceptibility testing results are needed to clear infections. MALDI-TOF MS is helpful for rapid identification and is capable of being resistant to many routinely used antibiotics, including carbapenems.
  25 in total

1.  Classification of Ralstonia pickettii biovar 3/'thomasii' strains (Pickett 1994) and of new isolates related to nosocomial recurrent meningitis as Ralstonia mannitolytica sp. nov.

Authors:  T De Baere; S Steyaert; G Wauters; P Des Vos; J Goris; T Coenye; T Suyama; G Verschraegen; M Vaneechoutte
Journal:  Int J Syst Evol Microbiol       Date:  2001-03       Impact factor: 2.747

2.  Bacteremia due to Ralstonia mannitolilytica: A report of the first case in Peru.

Authors:  Giancarlo Pérez Lazo; Wilmer Silva Caso; Adriana Morales Moreno; Fernando Soto Febres; Liliana Morales Castillo; Hugo Jove Químper; Juana Del Valle Mendoza; Miguel Angel Aguilar Luis; Ronald Aquino Ortega
Journal:  Medwave       Date:  2021-05-26

3.  Ralstonia infection among hemodialysis patients: A summary.

Authors:  Won Sriwijitalai; Viroj Wiwanitkit
Journal:  Saudi J Kidney Dis Transpl       Date:  2019 May-Jun

4.  Characterization of clinically isolated Ralstonia mannitolilytica strains using random amplification of polymorphic DNA (RAPD) typing and antimicrobial sensitivity, and comparison of the classification efficacy of phenotypic and genotypic assays.

Authors:  Florian Daxboeck; Maria Stadler; Ojan Assadian; Eva Marko; Alexander M Hirschl; Walter Koller
Journal:  J Med Microbiol       Date:  2005-01       Impact factor: 2.472

Review 5.  Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.

Authors:  David Lebeaux; Jean-Marc Ghigo; Christophe Beloin
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

Review 6.  Ralstonia mannitolilytica bacteraemia: a case report and literature review.

Authors:  Matteo Boattini; Gabriele Bianco; Luigi Biancone; Rossana Cavallo; Cristina Costa
Journal:  Infez Med       Date:  2018-12-01

7.  Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to 16S rRNA gene sequencing for species identification of nonfermenting bacteria.

Authors:  A Mellmann; J Cloud; T Maier; U Keckevoet; I Ramminger; P Iwen; J Dunn; G Hall; D Wilson; P Lasala; M Kostrzewa; D Harmsen
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

8.  Factors associated with Pseudomonas pickettii intrinsic contamination of commercial respiratory therapy solutions marketed as sterile.

Authors:  R L Anderson; L A Bland; M S Favero; M M McNeil; B J Davis; D C Mackel; C R Gravelle
Journal:  Appl Environ Microbiol       Date:  1985-12       Impact factor: 4.792

9.  Ralstonia mannitolilytica infection in renal transplant recipient: first report.

Authors:  C Mukhopadhyay; A Bhargava; A Ayyagari
Journal:  Indian J Med Microbiol       Date:  2003 Oct-Dec       Impact factor: 0.985

10.  Ralstonia mannitolilytica sepsis: a case report.

Authors:  Michael Owusu; Godfred Acheampong; Augustina Annan; Kwadwo Sarfo Marfo; Isaac Osei; John Amuasi; Nimako Sarpong; Justin Im; Ondari D Mogeni; Hsin-Ying Chiang; Chih-Horng Kuo; Hyon Jin Jeon; Ursula Panzner; Se Eun Park; Florian Marks; Ellis Owusu-Dabo; Yaw Adu-Sarkodie
Journal:  J Med Case Rep       Date:  2019-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.